JP2007501281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501281A5 JP2007501281A5 JP2006533395A JP2006533395A JP2007501281A5 JP 2007501281 A5 JP2007501281 A5 JP 2007501281A5 JP 2006533395 A JP2006533395 A JP 2006533395A JP 2006533395 A JP2006533395 A JP 2006533395A JP 2007501281 A5 JP2007501281 A5 JP 2007501281A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- pharmaceutical formulation
- use according
- treprostinil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960005032 treprostinil Drugs 0.000 claims description 6
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 239000000155 melt Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- -1 treprostinil Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001110 prostacyclinlike Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47240703P | 2003-05-22 | 2003-05-22 | |
| US60/472,407 | 2003-05-22 | ||
| PCT/US2004/016401 WO2005007081A2 (en) | 2003-05-22 | 2004-05-24 | Compounds and methods for delivery of prostacyclin analogs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012063484A Division JP2012162539A (ja) | 2003-05-22 | 2012-03-21 | プロスタサイクリン類似体の送達のための化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007501281A JP2007501281A (ja) | 2007-01-25 |
| JP2007501281A5 true JP2007501281A5 (https=) | 2012-06-28 |
| JP5043433B2 JP5043433B2 (ja) | 2012-10-10 |
Family
ID=34079029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533395A Expired - Lifetime JP5043433B2 (ja) | 2003-05-22 | 2004-05-24 | プロスタサイクリン類似体の送達のための化合物及び方法 |
| JP2012063484A Withdrawn JP2012162539A (ja) | 2003-05-22 | 2012-03-21 | プロスタサイクリン類似体の送達のための化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012063484A Withdrawn JP2012162539A (ja) | 2003-05-22 | 2012-03-21 | プロスタサイクリン類似体の送達のための化合物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (19) | US7417070B2 (https=) |
| EP (2) | EP1628654B2 (https=) |
| JP (2) | JP5043433B2 (https=) |
| KR (1) | KR101072339B1 (https=) |
| CN (4) | CN101780092B (https=) |
| CA (4) | CA2736406C (https=) |
| ES (2) | ES2622471T5 (https=) |
| WO (1) | WO2005007081A2 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10214983A1 (de) * | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| ES2622471T5 (es) * | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
| US20090124697A1 (en) * | 2003-12-16 | 2009-05-14 | United Therapeutics Corporation | Inhalation formulations of treprostinil |
| DE602004028155D1 (de) * | 2003-12-16 | 2010-08-26 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von ischämischen läsionen |
| ATE441418T1 (de) * | 2003-12-16 | 2009-09-15 | United Therapeutics Corp | Verwendung von treprostinil zur verbesserung der nierenfunktion |
| WO2005099680A2 (en) | 2004-04-12 | 2005-10-27 | United Therapeutics, Inc. | Use of treprostinil to treat neuropathic diabetic foot ulcers |
| WO2006130879A2 (en) * | 2005-06-02 | 2006-12-07 | The Regents Of The University Of Colorado | Uses of prostacyclin analogs |
| US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
| EP2026816B1 (en) * | 2006-05-15 | 2018-10-24 | United Therapeutics Corporation | Treprostinil administration using a metered dose inhaler |
| DE102006026786A1 (de) | 2006-06-07 | 2007-12-13 | Joachim Kern | Dosierinhalator |
| US20090036465A1 (en) * | 2006-10-18 | 2009-02-05 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| US20100048693A1 (en) * | 2006-12-04 | 2010-02-25 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of COPD |
| JP2010518122A (ja) * | 2007-02-09 | 2010-05-27 | ユナイテッド セラピューティクス コーポレーション | 間質性肺疾患および喘息のためのトレプロスチニル処置 |
| CN101903324B (zh) * | 2007-12-17 | 2013-07-03 | 联合治疗公司 | 一种制备Remodulin中的活性成分曲前列素的改良方法 |
| CA2723540C (en) * | 2008-05-08 | 2016-01-05 | United Therapeutics Corporation | Treprostinil monohydrate |
| WO2009158010A1 (en) * | 2008-06-27 | 2009-12-30 | Concert Pharmaceuticals, Inc. | Prostacyclin analogs |
| US8349892B2 (en) * | 2009-05-07 | 2013-01-08 | United Therapeutics Corporation | Solid formulations of prostacyclin analogs |
| CN101891596B (zh) * | 2009-05-22 | 2013-12-11 | 上海天伟生物制药有限公司 | 一种化合物及其制备方法和用途 |
| DE102009031274A1 (de) | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
| RS53234B (sr) * | 2009-08-07 | 2014-08-29 | Scipharm Sàrl | Kompozicija za lečenje cistične fibroze |
| ES2611187T3 (es) | 2010-03-15 | 2017-05-05 | United Therapeutics Corporation | Tratamiento para hipertensión pulmonar |
| JP6046034B2 (ja) | 2010-06-03 | 2016-12-14 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの製造 |
| US20120004307A1 (en) * | 2010-06-15 | 2012-01-05 | United Therapeutics Corporation | Oral treatment of digital ischemic lesions |
| CA2710725C (en) | 2010-07-22 | 2017-08-01 | Alphora Research Inc. | Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation |
| CA2726599C (en) | 2010-12-30 | 2017-07-25 | Alphora Research Inc. | Process for treprostinil salt preparation |
| US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
| US20130345471A1 (en) | 2011-03-02 | 2013-12-26 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
| CN103193626B (zh) | 2012-01-10 | 2016-05-11 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| CN103193627B (zh) | 2012-01-10 | 2016-04-20 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| US9387214B2 (en) | 2012-01-13 | 2016-07-12 | United Therapeutics Corporation | Method of identifying therapies for pulmonary hypertension |
| LT2674413T (lt) * | 2012-06-15 | 2017-09-25 | Scipharm Sąrl | Treprostinilo ir jo darinių gavimo būdas |
| AU2013351934B2 (en) * | 2012-11-30 | 2018-03-29 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| CN104837806A (zh) * | 2012-12-07 | 2015-08-12 | 开曼化学股份有限公司 | 前列环素类似物的合成方法 |
| CN103880801B (zh) * | 2012-12-20 | 2017-11-03 | 江苏盛迪医药有限公司 | 一种制备曲前列尼尔的中间体、其制备方法以及通过其制备曲前列尼尔的方法 |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (en) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| JP2016517410A (ja) * | 2013-03-14 | 2016-06-16 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの固体形態 |
| CN109608326A (zh) * | 2013-03-15 | 2019-04-12 | 联合治疗公司 | 曲前列环素的盐 |
| JP6263604B2 (ja) | 2013-03-25 | 2018-01-17 | ユナイテッド セラピューティクス コーポレイション | チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法 |
| US9758465B2 (en) | 2013-04-30 | 2017-09-12 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| ES2860975T3 (es) * | 2013-10-25 | 2021-10-05 | Insmed Inc | Compuestos de prostaciclina |
| US9895465B2 (en) | 2014-03-12 | 2018-02-20 | Pioneer Surgical Technology, Inc. | Absorbable compositions and methods for their use in hemostasis |
| ES2908142T3 (es) | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| JP6561109B2 (ja) * | 2014-07-16 | 2019-08-14 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| WO2016038532A1 (en) | 2014-09-09 | 2016-03-17 | Mylan Laboratories Limited | Amorphous treprostinil diethanolamine |
| HU231186B1 (hu) * | 2014-10-08 | 2021-06-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Új eljárás treprostinil és sói előállítására |
| US9593061B2 (en) | 2014-10-20 | 2017-03-14 | United Therapeutics Corporation | Synthesis of intermediates for producing prostacyclin derivatives |
| AU2015349969B2 (en) * | 2014-11-18 | 2020-02-06 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) * | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| CA2967899C (en) | 2014-12-03 | 2023-09-19 | Steadymed Ltd | Preservative-free treprostinil formulations and methods and devices for use with same |
| CN104783298A (zh) * | 2015-03-24 | 2015-07-22 | 湖州珍贝羊绒制品有限公司 | 一种生物灭菌组合物及其纳米乳的制备与应用 |
| US20160318844A1 (en) * | 2015-04-29 | 2016-11-03 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US11069054B2 (en) | 2015-12-30 | 2021-07-20 | Visiongate, Inc. | System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy |
| IL262720B2 (en) | 2016-05-05 | 2024-06-01 | Liquidia Tech Inc | Dry powder treprostinil for the treatment of pulmonary hypertension |
| RU2757903C2 (ru) * | 2016-09-15 | 2021-10-22 | Камурус Аб | Препараты аналогов простациклина |
| JP7220650B2 (ja) * | 2016-09-26 | 2023-02-10 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルプロドラッグ |
| KR20190109399A (ko) | 2016-12-05 | 2019-09-25 | 코세어 파마 인코포레이티드 | 트레프로스티닐 및 이의 염의 피부 및 경피 투여 |
| US10799653B2 (en) | 2017-01-09 | 2020-10-13 | United Therapeutics Corporation | Aerosol delivery device and method for manufacturing and operating the same |
| EP3498283A1 (en) * | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| HU231296B1 (hu) * | 2018-03-09 | 2022-09-28 | Chinoin Zrt | Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására |
| IL278513B (en) * | 2018-05-07 | 2022-09-01 | Pharmosa Biopharm Inc | A pharmaceutical preparation for the controlled release of treprostinil |
| ES2976468T3 (es) * | 2018-09-18 | 2024-08-01 | Lilly Co Eli | Sal de treprostinil erbumina |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| EP4017588A1 (en) | 2019-08-23 | 2022-06-29 | United Therapeutics Corporation | Treprostinil prodrugs |
| US10781160B1 (en) * | 2019-10-04 | 2020-09-22 | Chirogate International Inc. | Hexadecyl Treprostinil crystals and methods for preparation thereof |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
| JP2023523557A (ja) | 2020-04-17 | 2023-06-06 | ユナイテッド セラピューティクス コーポレイション | 間質性肺疾患の治療における使用のためのトレプロスチニル |
| IL298591A (en) | 2020-06-09 | 2023-01-01 | United Therapeutics Corp | Pomeryl dictopiperidine prodrugs of treprostinil |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| WO2022094100A1 (en) * | 2020-10-28 | 2022-05-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| US11447440B2 (en) | 2020-10-29 | 2022-09-20 | Chirogate International Inc. | Treprostinil monohydrate crystals and methods for preparation thereof |
| KR20250133451A (ko) * | 2020-12-14 | 2025-09-05 | 유나이티드 쎄러퓨틱스 코포레이션 | 트레프로스티닐 프로드러그로 질환을 치료하는 방법 |
| JP2024510930A (ja) | 2021-03-03 | 2024-03-12 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニル及びそのプロドラッグの乾燥粉末組成物、及び、さらに（ｅ）－３，６－ビス［４－（ｎ－カルボニル－２－プロペニル）アミドブチル］－２，５－ジケトピペラジン（ｆｄｋｐ）を含む乾燥粉末組成物 |
| CN113552265B (zh) * | 2021-09-17 | 2022-01-04 | 天地恒一制药股份有限公司 | 富马酸丙酚替诺福韦合成原料中杂质的检测方法及应用 |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| WO2023154705A1 (en) | 2022-02-08 | 2023-08-17 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| EP4516297A4 (en) | 2022-04-29 | 2026-02-25 | Zhaoke pharmaceutical guangzhou co ltd | Treprostinil Gentle Inhalation Mist |
| US20240139207A1 (en) | 2022-10-31 | 2024-05-02 | United Therapeutics Corporation | Methods for treating pulmonary hypertension |
| EP4652151A1 (en) * | 2023-01-19 | 2025-11-26 | United Therapeutics Corporation | Treprostinil analogs |
| CN117800845B (zh) * | 2023-03-28 | 2026-04-14 | 广州楷石医药有限公司 | 一种羟基取代曲前列尼尔衍生物、合成方法及其应用 |
| IL326413A (en) | 2023-08-08 | 2026-04-01 | United Therapeutics Corp | Method for producing an oral pharmaceutical osmotic system and a pharmaceutical batch produced using the same method |
| US20250197338A1 (en) | 2023-11-09 | 2025-06-19 | United Therapeutics Corporation | Syntheses of compounds useful for producing treprostinil |
| US20260041656A1 (en) | 2024-08-06 | 2026-02-12 | United Therapeutics Corporation | Treating pulmonary hypertension based on novel biomarker |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US515322A (en) * | 1894-02-27 | Railroad-car | ||
| US3515222A (en) * | 1968-06-19 | 1970-06-02 | American Tractor Equip Corp | Cable plow mounting |
| US4490537A (en) | 1977-04-19 | 1984-12-25 | The Upjohn Company | Enlarged-hetero-ring prostacyclin analogs |
| US4525586A (en) | 1980-02-28 | 1985-06-25 | The Upjohn Company | Composition and process |
| US4338457A (en) * | 1980-02-28 | 1982-07-06 | The Upjohn Company | Composition and process |
| CA1201712A (en) * | 1980-02-28 | 1986-03-11 | Paul A. Aristoff | Carbacyclin analogs |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| US4420632A (en) | 1980-04-15 | 1983-12-13 | The Upjohn Company | Composition and process |
| US4306076A (en) * | 1980-04-23 | 1981-12-15 | The Upjohn Company | Inter-phenylene CBA compounds |
| US4349689A (en) * | 1980-12-22 | 1982-09-14 | The Upjohn Company | Methano carbacyclin analogs |
| US4434164A (en) | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Crystalline benzothiazine dioxide salts |
| US4486598A (en) | 1982-02-22 | 1984-12-04 | The Upjohn Company | Carbacyclin analogs |
| DE3315356A1 (de) | 1982-04-30 | 1983-11-17 | Ono Pharmaceutical Co. Ltd., Osaka | Verwendung von prostaglandinanalogen |
| US4561604A (en) | 1983-07-18 | 1985-12-31 | Shimano Industrial Company Limited | Spinning reel |
| FI67490C (fi) | 1983-11-02 | 1985-04-10 | Fluilogic Systems Oy | Filtreringsenhet |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US4683330A (en) | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| US4668814A (en) * | 1984-03-08 | 1987-05-26 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| DE3448257C2 (en) * | 1984-07-25 | 1988-08-18 | Schering Ag, 1000 Berlin Und 4709 Bergkamen, De | Cytoprotective action of prostacyclin derivatives on the kidney |
| US5663203A (en) * | 1986-09-11 | 1997-09-02 | Schering Aktiengesellschaft | Agents containing prostacyclin derivatives for topical application |
| GB8824187D0 (en) | 1988-10-14 | 1988-11-23 | Wellcome Found | Compounds for use in medicine |
| GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
| US5545671A (en) * | 1989-10-05 | 1996-08-13 | Schering Aktiengesellschaft | Antimetastically acting agents |
| GB9011588D0 (en) * | 1990-05-24 | 1990-07-11 | Wellcome Found | Prostaglandin analogues for use in medicine |
| DE4104606C1 (https=) * | 1991-02-12 | 1992-10-15 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | |
| US5496850A (en) * | 1991-04-11 | 1996-03-05 | Toray Industries, Inc. | Antimetastasis agent of malignant tumors |
| DE4135193C1 (https=) | 1991-10-22 | 1993-03-11 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | |
| US5190972A (en) | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
| DE4202665A1 (de) | 1992-01-28 | 1993-07-29 | Schering Ag | Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose |
| US6171786B1 (en) | 1992-09-17 | 2001-01-09 | Board Of Trustees Of University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
| US5466203A (en) * | 1994-03-30 | 1995-11-14 | Chen; George | Magnetically controlled load adjusting structure of gymnastic apparatus |
| DE69735002T2 (de) | 1996-10-25 | 2006-10-26 | Shire Laboratories, Inc. | Osmotisches Verabreichungssystem für lösliche Dosen |
| WO1998041210A1 (en) | 1997-03-14 | 1998-09-24 | Toray Industries, Inc. | Sustained-release prostaglandin i derivative preparation |
| US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
| GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| WO1999021830A1 (en) | 1997-10-24 | 1999-05-06 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| US6441245B1 (en) * | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| KR100638684B1 (ko) * | 1997-11-14 | 2006-10-27 | 유나이티드 세러퓨틱스 코오포레이션 | 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도 |
| US20010038855A1 (en) | 1998-06-05 | 2001-11-08 | Desjardin Michael A. | Dosage form for administering prescribed dose |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| WO2000055314A2 (en) * | 1999-03-18 | 2000-09-21 | United Therapeutics Corporation | Inhibitors of endothelin-1 synthesis |
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| CA2359652A1 (en) * | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6242482B1 (en) * | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| AU2001278115A1 (en) * | 2000-08-04 | 2002-02-18 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| AU2002241538A1 (en) | 2000-12-01 | 2002-07-24 | Nephros Therapeutics, Inc. | Intrasvascular drug delivery device and use therefor |
| US6700025B2 (en) | 2001-01-05 | 2004-03-02 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| US20030108512A1 (en) * | 2001-12-10 | 2003-06-12 | Robert Shorr | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer |
| US6803386B2 (en) * | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
| US7132453B2 (en) | 2002-03-15 | 2006-11-07 | Vanderbilt University | Method of using prostacyclin to treat respiratory syncytial virus infections |
| DE10214983A1 (de) * | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| ES2622471T5 (es) * | 2003-05-22 | 2020-07-23 | United Therapeutics Corp | Compuestos y procedimientos para la administración de análogos de prostaciclina |
| US20050101608A1 (en) | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| US20050254032A1 (en) * | 2003-11-13 | 2005-11-17 | Fuji Photo Film Co., Ltd. | Exposure device |
| DE602004028155D1 (de) | 2003-12-16 | 2010-08-26 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von ischämischen läsionen |
| JP2010518122A (ja) | 2007-02-09 | 2010-05-27 | ユナイテッド セラピューティクス コーポレーション | 間質性肺疾患および喘息のためのトレプロスチニル処置 |
| CN101903324B (zh) * | 2007-12-17 | 2013-07-03 | 联合治疗公司 | 一种制备Remodulin中的活性成分曲前列素的改良方法 |
| CA2723540C (en) * | 2008-05-08 | 2016-01-05 | United Therapeutics Corporation | Treprostinil monohydrate |
| JP2010244388A (ja) * | 2009-04-08 | 2010-10-28 | Pioneer Electronic Corp | 情報提供装置、情報提供方法、及び情報提供用プログラム |
| US8349892B2 (en) | 2009-05-07 | 2013-01-08 | United Therapeutics Corporation | Solid formulations of prostacyclin analogs |
| JP6046034B2 (ja) * | 2010-06-03 | 2016-12-14 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルの製造 |
-
2004
- 2004-05-24 ES ES04776104T patent/ES2622471T5/es not_active Expired - Lifetime
- 2004-05-24 CA CA2736406A patent/CA2736406C/en not_active Expired - Lifetime
- 2004-05-24 EP EP04776104.4A patent/EP1628654B2/en not_active Expired - Lifetime
- 2004-05-24 CA CA2851309A patent/CA2851309C/en not_active Expired - Lifetime
- 2004-05-24 CN CN2009101787386A patent/CN101780092B/zh not_active Expired - Lifetime
- 2004-05-24 CA CA2526534A patent/CA2526534C/en not_active Expired - Lifetime
- 2004-05-24 WO PCT/US2004/016401 patent/WO2005007081A2/en not_active Ceased
- 2004-05-24 JP JP2006533395A patent/JP5043433B2/ja not_active Expired - Lifetime
- 2004-05-24 CN CN2008100861999A patent/CN101265226B/zh not_active Expired - Lifetime
- 2004-05-24 CN CNB2004800205699A patent/CN100558351C/zh not_active Expired - Lifetime
- 2004-05-24 CN CN2012101586478A patent/CN102697790A/zh active Pending
- 2004-05-24 CA CA2959852A patent/CA2959852A1/en not_active Abandoned
- 2004-05-24 EP EP14162471.8A patent/EP2792353B1/en not_active Expired - Lifetime
- 2004-05-24 US US10/851,481 patent/US7417070B2/en active Active
- 2004-05-24 ES ES14162471.8T patent/ES2670872T3/es not_active Expired - Lifetime
-
2005
- 2005-07-26 US US11/189,072 patent/US8410169B2/en not_active Expired - Fee Related
- 2005-11-22 KR KR1020057022319A patent/KR101072339B1/ko not_active Expired - Lifetime
-
2006
- 2006-11-22 US US11/603,124 patent/US7384978B2/en not_active Expired - Lifetime
- 2006-11-22 US US11/603,116 patent/US7544713B2/en not_active Expired - Lifetime
- 2006-11-22 US US11/603,219 patent/US20070078095A1/en not_active Abandoned
-
2008
- 2008-04-08 US US12/078,955 patent/US8252839B2/en not_active Expired - Lifetime
-
2011
- 2011-01-25 US US13/013,155 patent/US8232316B2/en not_active Expired - Lifetime
-
2012
- 2012-03-21 JP JP2012063484A patent/JP2012162539A/ja not_active Withdrawn
- 2012-07-26 US US13/558,757 patent/US8536363B2/en not_active Expired - Fee Related
-
2013
- 2013-05-31 US US13/906,585 patent/US9050311B2/en not_active Expired - Lifetime
-
2014
- 2014-09-18 US US14/490,014 patent/US9199908B2/en not_active Expired - Lifetime
-
2015
- 2015-05-13 US US14/710,694 patent/US9278901B2/en not_active Expired - Lifetime
- 2015-10-13 US US14/881,379 patent/US9422223B2/en not_active Expired - Lifetime
- 2015-10-28 US US14/925,084 patent/US9624156B2/en not_active Expired - Fee Related
-
2016
- 2016-08-17 US US15/239,014 patent/US9878972B2/en not_active Expired - Fee Related
-
2018
- 2018-01-19 US US15/875,101 patent/US20180141891A1/en not_active Abandoned
-
2019
- 2019-07-23 US US16/519,491 patent/US10947177B2/en not_active Expired - Fee Related
-
2020
- 2020-02-07 US US16/784,720 patent/US20200181057A1/en not_active Abandoned
-
2021
- 2021-10-06 US US17/495,141 patent/US11292758B2/en not_active Expired - Lifetime
-
2022
- 2022-04-04 US US17/712,566 patent/US20220289660A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007501281A5 (https=) | ||
| JP6508544B2 (ja) | 腫瘍を治療するための薬用組成物 | |
| ES2241603T3 (es) | Formulacion oral para la administracion al ileon que comprende un compuesto inhibidor del transporte de acidos biliares presentes en el ileon. | |
| ES2390661T5 (es) | Forma de presentación para administración por vía oral para éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o sus sales | |
| JP4489356B2 (ja) | 浸透促進剤 | |
| JP2004514663A5 (https=) | ||
| CZ413497A3 (cs) | Formulace s řízeným uvolňováním u špatně rozpustného léčiva | |
| WO2008018569A1 (en) | Pharmaceutical composition | |
| JP2004511521A (ja) | 回腸胆汁輸送の阻害化合物とＨＭＧ−ＣｏＡレダクターゼ阻害剤を含んでなる経口製剤 | |
| ES2324009B1 (es) | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. | |
| JP7278413B2 (ja) | アピキサバン含有微粒球製造用分散相組成物およびそれから製造された生体適合性ポリマー系アピキサバン含有微粒球 | |
| JP2002505323A5 (https=) | ||
| JP6265999B2 (ja) | 光学活性のトルバプタンを含む注射用持効性製剤及びその製造方法 | |
| JP2000512993A (ja) | Ｈ▲上＋▼，ｋ▲上＋▼−ａｔｐアーゼ阻害剤の投与計画 | |
| JP5113323B2 (ja) | ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物 | |
| PL195272B1 (pl) | Zastosowania kwasu alendronowego lub jego farmaceutycznie dopuszczalnej soli lub ich mieszaniny | |
| JP4290381B2 (ja) | ピリドンカルボン酸化合物含有エマルション | |
| JP2013536243A5 (https=) | ||
| JP2022173401A (ja) | 結晶 | |
| JP2004520398A (ja) | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 | |
| JPH0710772B2 (ja) | 一定の放出性を保持した薬物粒子 | |
| JP2012517466A (ja) | 制御されたドラッグデリバリーのための生体分解性担体を含む組成物 | |
| NZ224497A (en) | Pharmaceutical composition comprising flunarizine | |
| TW201605488A (zh) | 用以預防及／或治療多囊腎病之藥物 | |
| CN1181819C (zh) | 使用五氟苯磺酰胺的综合疗法 |